{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:17:28Z","timestamp":1767143848512,"version":"build-2238731810"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40261-022-01207-w","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:03:07Z","timestamp":1665637387000},"page":"999-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-9829","authenticated-orcid":false,"given":"George","family":"Gourzoulidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Koulentaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonis","family":"Kattamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bouzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chara","family":"Giatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Chotzagiannoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Beletsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kourlaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"issue":"1","key":"1207_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.htct.2019.01.013","volume":"42","author":"CV Medawar","year":"2020","unstructured":"Medawar CV, Mosegui GBG, Vianna CMM, et al. PEG-asparaginase and native Escherichia coli l-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review. Hematol Transfus Cell Ther. 2020;42(1):54\u201361. https:\/\/doi.org\/10.1016\/j.htct.2019.01.013.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"Suppl 5","key":"1207_CR2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdw025.","journal-title":"Ann Oncol"},{"key":"1207_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-1-4615-4811-9_69","volume":"457","author":"BL Asselin","year":"1999","unstructured":"Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621\u20139.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1207_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","volume":"44","author":"VI Avramis","year":"2005","unstructured":"Avramis VI, Panosyan EH. Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367\u201393. https:\/\/doi.org\/10.2165\/00003088-200544040-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1207_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95\u201301 for children with acute lymphoblastic leukemia. Blood. 2007;109(3):896\u2013904. https:\/\/doi.org\/10.1182\/blood-2006-06-027714.","journal-title":"Blood"},{"issue":"5","key":"1207_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.v97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91\u201301. Blood. 2001;97(5):1211\u20138. https:\/\/doi.org\/10.1182\/blood.v97.5.1211.","journal-title":"Blood"},{"issue":"2","key":"1207_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166\u201378. https:\/\/doi.org\/10.1056\/NEJMra052603.","journal-title":"N Engl J Med"},{"issue":"6","key":"1207_CR8","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"issue":"1","key":"1207_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1517\/14712590802586058","volume":"9","author":"A Zeidan","year":"2009","unstructured":"Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther. 2009;9(1):111\u20139. https:\/\/doi.org\/10.1517\/14712590802586058.","journal-title":"Expert Opin Biol Ther"},{"issue":"34","key":"1207_CR10","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","volume":"32","author":"AL Angiolillo","year":"2014","unstructured":"Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli l-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children\u2019s Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34):3874\u201382.","journal-title":"J Clin Oncol"},{"key":"1207_CR11","unstructured":"European Medicines Agency (EMA). Available at: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/oncaspar. Accessed 30 June 2020."},{"issue":"8","key":"1207_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","volume":"33","author":"J Kurtzberg","year":"2011","unstructured":"Kurtzberg J, Asselin B, Bernstein M, et al. Polyethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children\u2019s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610\u20136. https:\/\/doi.org\/10.1097\/MPH.0b013e31822d4d4e.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"1207_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8.P","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(14)70243-8.P.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1207_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199\u2013209. https:\/\/doi.org\/10.1016\/S1470-2045(12)70600-9.","journal-title":"Lancet Oncol"},{"key":"1207_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-6955-2-2","volume":"2","author":"S Haithcox","year":"2003","unstructured":"Haithcox S, Ramnes CR, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs. 2003;2:2.","journal-title":"BMC Nurs"},{"issue":"16","key":"1207_CR16","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/s1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05\u2013001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(15)00363-0.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1207_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13561-019-0257-3","volume":"9","author":"X Hu","year":"2019","unstructured":"Hu X, Wildman K, Basu S, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Econ Rev. 2019;9(1):40.","journal-title":"Health Econ Rev."},{"key":"1207_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/cer-2018-0076","volume":"8","author":"G Gourzoulidis","year":"2019","unstructured":"Gourzoulidis G, Maniadakis N, Petrakis D, et al. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. J Comp Effect Res. 2019;8:133\u201342. https:\/\/doi.org\/10.2217\/cer-2018-0076.","journal-title":"J Comp Effect Res."},{"key":"1207_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/meg.0000000000001916","volume":"33","author":"K Vellopoulou","year":"2021","unstructured":"Vellopoulou K, Stefanou G, Tzanetakos C, et al. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol. 2021;33:325\u201333. https:\/\/doi.org\/10.1097\/meg.0000000000001916.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1207_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2013. Available at: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/involvement-and-participation. Accessed 1 Feb 2020."},{"key":"1207_CR21","unstructured":"European Network for Health Technology Assessment (EUnetHTA). Pharmacoeconomic guidelines around the world. May 2015. Available at: https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/03\/Methods_for_health_economic_evaluations.pdf. Accessed 10 Jan 2021."},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","volume":"59","author":"MJ Burke","year":"2018","unstructured":"Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade \u22653) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children\u2019s oncology group (COG) clinical trials. Leukemia Lymphoma. 2018;59:1624\u201333.","journal-title":"Leukemia Lymphoma."},{"key":"1207_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia. Cancer. 2011;117:238\u201349. https:\/\/doi.org\/10.1002\/cncr.25489.","journal-title":"Cancer"},{"issue":"2","key":"1207_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.25757","volume":"63","author":"LM Vrooman","year":"2016","unstructured":"Vrooman LM, Kirov II, Dreyer ZE, et al. Activity and toxicity of intravenous erwinia asparaginase following allergy to E coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(2):228\u201333. https:\/\/doi.org\/10.1002\/pbc.25757.","journal-title":"Pediatr Blood Cancer"},{"key":"1207_CR25","unstructured":"World Health Organization (WHO). Greece life tables. Available at: http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=60640. Accessed 30 June 2020."},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","volume":"55","author":"ML Graham","year":"2003","unstructured":"Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55:1293\u2013302. https:\/\/doi.org\/10.1016\/S0169-409X(03)00110-8.","journal-title":"Adv Drug Deliv Rev"},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","volume":"28","author":"HJ M\u00fcller","year":"1998","unstructured":"M\u00fcller HJ, Boos J. Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97\u2013113. https:\/\/doi.org\/10.1016\/S1040-8428(98)00015-8.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"1207_CR28","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","volume":"59","author":"MJ Burke","year":"2018","unstructured":"Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade \u22653) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children\u2019s oncology group (COG) clinical trials. Leukemia lymphoma. 2018;59(7):1624\u201333. https:\/\/doi.org\/10.1080\/10428194.2017.1397658.","journal-title":"Leukemia lymphoma."},{"issue":"2","key":"1207_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia. Cancer. 2011;117(2):238\u201349. https:\/\/doi.org\/10.1002\/cncr.25489.","journal-title":"Cancer"},{"key":"1207_CR30","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Available at: https:\/\/link.springer.com\/chapter\/10.1007\/978-94-007-7596-1_3. 2014. Accessed 30 June 2020.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"1207_CR31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/pbc.24096","volume":"59","author":"W Furlong","year":"2012","unstructured":"Furlong W, Rae C, Feeny D, et al. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59:717\u201324.","journal-title":"Pediatr Blood Cancer"},{"key":"1207_CR32","unstructured":"National Institute for Health and Clinical Excellence (NICE). NICE clinical guideline 134. Anaphylaxis. Available at: http:\/\/www.nice.org.uk\/guidance\/cg134\/evidence\/anaphylaxis-full-guideline-184946941. Accessed 1 Feb 2020."},{"key":"1207_CR33","unstructured":"Greek Ministry of Health. Drug price bulletin 2020. Available at: https:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/deltia-timwn. Accessed 30 June 2020."},{"key":"1207_CR34","unstructured":"Pharmaceutical Research and Technology company (I.F.E.T.). List of medicines. Available at: https:\/\/www.ifet.gr\/en\/. Accessed 30 June 2020."},{"key":"1207_CR35","unstructured":"Greek Ministry of Health. DRG code: \u03a322X. Diagnostic related groups. 2020. Available at: http:\/\/kenicd.e-healthnet.gr\/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a322%ce%9c. Accessed 30 June 2020."},{"key":"1207_CR36","unstructured":"Greek Ministry of Health. DRG code: \u03a661\u0391. Diagnostic related groups. Available at: http:\/\/kenicd.e-healthnet.gr\/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a661%ce%91. Accessed 30 June 2020."},{"key":"1207_CR37","unstructured":"Greek Ministry of Health. DRG code: \u03a122\u039c. Diagnostic related groups. Available at: http:\/\/kenicd.e-healthnet.gr\/KEN%CE%91%CE%BD%CE%B1%CE%BB%CF%85%CF%84%CE%B9%CE%BA%CE%AC.aspx?iditem=%ce%a122%ce%9c. Accessed 30 June 2020."},{"issue":"9","key":"1207_CR38","doi-asserted-by":"publisher","first-page":"PA443","DOI":"10.1016\/j.jval.2017.08.257","volume":"20","author":"G Gourzoulidis","year":"2017","unstructured":"Gourzoulidis G, Vassilopoulos G, Gialama F, et al. Economic evaluation of dasatinib compared to nilotinib as second line treatment of chronic myeloid leukemia in Greece. Value Health. 2017;20(9):PA443.","journal-title":"Value Health."},{"key":"1207_CR39","unstructured":"National Organization for Healthcare Services Provision (EOPYY). Available at: https:\/\/www.eopyy.gov.gr\/. Accessed 30 June 2020."},{"key":"1207_CR40","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19:929\u201335. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health."},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, et al. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36:509\u201322. https:\/\/doi.org\/10.1007\/s40273-017-0606-1.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1207_CR42","doi-asserted-by":"publisher","first-page":"1447828","DOI":"10.1080\/16549716.2018.1447828","volume":"11","author":"D Cameron","year":"2018","unstructured":"Cameron D, Ubels J, Norstr\u00f6m F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11(1):1447828. https:\/\/doi.org\/10.1080\/16549716.2018.1447828.","journal-title":"Glob Health Action."},{"issue":"Suppl 3","key":"1207_CR43","doi-asserted-by":"publisher","first-page":"S772","DOI":"10.1016\/j.jval.2019.09.1963","volume":"22","author":"C Tzanetakos","year":"2019","unstructured":"Tzanetakos C, Stefanou G, Gourzoulidis G. PNS61 does a standard willingness-to-pay threshold exist in Greece? Value Health. 2019;22(Suppl 3):S772\u20133. https:\/\/doi.org\/10.1016\/j.jval.2019.09.1963.","journal-title":"Value Health."},{"key":"1207_CR44","unstructured":"International Monetary Fund. World Economic Outlook Database 2020. Available at: https:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2019\/02\/weodata\/index.aspx. Accessed 30 June 2020"},{"issue":"5","key":"1207_CR45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3324\/haematol.2012.073510","volume":"98","author":"WH Tong","year":"2013","unstructured":"Tong WH, van der Sluis IM, Alleman CJ, et al. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica. 2013;98(5):753\u20139. https:\/\/doi.org\/10.3324\/haematol.2012.073510.","journal-title":"Haematologica"},{"issue":"3","key":"1207_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00043426-200203000-00004","volume":"24","author":"HA Kurre","year":"2002","unstructured":"Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children\u2019s Cancer Group study (CCG-1962). J Pediatr Hematol Oncol. 2002;24(3):175\u201381. https:\/\/doi.org\/10.1097\/00043426-200203000-00004.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"1207_CR47","first-page":"388","volume":"30","author":"BG Peters","year":"1995","unstructured":"Peters BG, Goeckner BJ, Ponzillo JJ, et al. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary. 1995;30(7):388\u201393.","journal-title":"Formulary"}],"updated-by":[{"DOI":"10.1007\/s40261-022-01236-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01207-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01207-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01207-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T02:18:56Z","timestamp":1672366736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01207-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01207-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"26 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01236-5","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01236-5","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Econcare LP received research grant funding from Servier Hellas. AB and VC were Servier Hellas employees at the time of this study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was sponsored by Servier Hellas. The study sponsor had no interference in the study design, data collection, or writing of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was an economic evaluation analysis and does not involve human subjects. Input data including human material or human data derived from other published studies was performed with the approval of an appropriate Ethics Committee; therefore, ethics approval was not required for the performance of this cost-effectiveness analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All data used to conduct this study are included in this published article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"GG and MK conducted the analyses, collected the data, and interpreted the results. GG wrote the manuscript. AK, MB, and CG were the local clinical experts who provided local resource utilization data and contributed to data validation and interpretation of the results. VC, AB, and GK contributed to interpretation of the results and manuscript writing. All authors reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}